Biomeasure Incorporated

The Administrators of the Tulane Educational Fund

Ipsen Pharma S.a.s.

Societe De Conseils De Recherches Et D'applications Scientifiques Sas

Kinerton Limited

Other

New York University

Poly-med, Inc.

Ipsen Manufacturing Ireland Limited

Tulane Educational Fund

The Administration of the Tulane Educational Fund

Ipsen Pharma

Jacques-Pierre Moreau

Sun H Kim

David H Coy

Shalaby Wahba Shalaby

Steven A Jackson

Zheng Xin Dong

Arthur E Bogden

Michael DeWitt Culler

John E Taylor

Francis X Ignatious

Ruth M Russell

Francis Ignatious

Roland Cherif-Cheikh

Judith P Kitchell

Fleur Strand

The present invention is directed to compounds according to formula,(RR)-A-(A-A-A-A-A-A-A-A)-A-R,and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.

Melanocortin receptor ligands

The present invention is directed to a compound according to formula,

Ligands of melanocortin receptors

Disclosed is a series of somatostatin-dopamine chimeric analogs which retain both somatostatin and dopamine activity in vivo. An example is: 6-n-propyl-8&#x3b2;-ergolinglmethylthioacetyl-D-Phe-c(Cys-Tyr-D-Trp-Lys-Abu-Cys)-Thr-NH.

Somatostatin-dopamine chimeric analogs

The invention features a method of administering one or more therapeutic agents to a patient and delivering said agent or agents continuously over an extended period of time, said method comprising: obtaining a pharmaceutical composition including a peptide carrier, one or more therapeutic agents, and up to 30 percent, by weight, of a pharmaceutically acceptable, soluble, monomeric carrier; and parenterally administering said pharmaceutical composition to a subject by injection, wherein said composition automatically forms a gel after interaction with the patient's bodily fluids and releases said peptide carrier and said agent or agents continuously within the patient over an extended period.

Sustained release drug formulations containing a carrier peptide

Disclosed is a series of somatostatin-dopamine chimeric analogs which retain both somatostatin and dopamine activity in vivo. An example is: 6-n-propyl-8&#x3b2;-ergolinglmethylthioacetyl-D-Phe-c-(Cys-Tyr-D-Trp-Lys-Abu-Cys)-Thr-NH.

Disclosed is a series of somatostatin-dopamine chimeric analogs which retain both somatostatin and dopamine activity in vivo. An example is:

This invention is directed to a sustained release composition comprised of Compound (A) having the formula or a pharmaceutically acceptable salt thereof, and a copolymer comprised of poly-(I)-lactic-glycolic-tartaric acid wherein the amino group of Compound (A) is ionically bound to a carboxyl group of the copolymer and wherein further the composition may be made into a sustained release pharmaceutical composition with pharmaceutically acceptable carrier(s).

Sustained release formulation of a peptide

A copolymer comprising an N-acylated derivative, and a composition comprising said copolymer and a polypeptide, said polypeptide comprising at least one effective ionogenic amine, wherein at least 50 percent, by weight, of said polypeptide present in said composition is ionically bound to said polymer.

Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides

A method of spherifying a sustained release ionic conjugate which contains a free carboxyl group-containing polymer and a free amino group-containing drug which are ionically bonded to each other.

Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides

A linear (i.e., non-cyclic) analog of biologically active amphibian bombesin, mammalian gastrin-releasing peptide (GRP), or mammalian growth hormone releasing factor (GRF), having an active site and a binding site responsible for the binding of the peptide to a receptor on a target cell. Cleavage of a peptide bond in the active site of naturally occurring bombesin, GRP, or GRF is unnecessary for in vivo biological activity. The analog has one of the following modifications: (a) a deletion of an amino acid residue within the active site and a modification of an amino acid residue outside of the active site, (b) a replacement of two amino acid residues within the active site with a synthetic amino acid, a &bgr;-amino acid, or a &ggr;-amino acid residue, or (c) a non-peptide bond instead of a peptide bond between an amino acid residue of the active site and an adjacent amino acid residue.

Growing community of inventors

Upton, MA, United States of America

Jacques-Pierre Moreau